Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
基本信息
- 批准号:8512810
- 负责人:
- 金额:$ 33.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-05 至 2016-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAftercareAlteplaseAlzheimer&aposs DiseaseAmericanAnimalsAnionsApoptosisApoptoticAstrocytesBrain DiseasesBrain InfarctionBrain InjuriesCause of DeathCell DeathCellsCessation of lifeClinicalClinical TrialsConnexinsCoupledCystineDNADeveloped CountriesDevelopmentDrug Delivery SystemsEventExcitatory Amino AcidsFDA approvedFibrinolytic AgentsFree Radical ScavengersGlutamatesHealthHigh Pressure Liquid ChromatographyHumanIn VitroIschemiaIschemic Brain InjuryLaboratoriesLeftMeasuresMicrodialysisMicrogliaMiddle Cerebral Artery OcclusionModelingMolecularMultiple SclerosisNecrosisNeurogliaNeuronsNeuroprotective AgentsNitrogenOxidation-ReductionOxidative StressOxygenPathologistPathway interactionsPatientsPharmaceutical PreparationsPharmacological TreatmentPlayProductionRadioactive TracersRattusReactionReactive Oxygen SpeciesRecurrenceReducing AgentsRelative (related person)ResearchRoleSmall Interfering RNAStrokeTechniquesTestingTissuesToxic effectTraumatic Brain InjuryWhole OrganismWorkacute strokeantiporterbrain tissuedesigndisabilityexperienceextracellularin vivoinhibitor/antagonistinjuredkillingsnervous system disordernitrosative stressnoveloxidative damageresponsestroke therapytool
项目摘要
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death and the leading cause for long-term disability in the U.S. and other industrialized nations. Each year 750,000 Americans suffer, and more than 150,000 die as a result of new and recurrent strokes. In spite of extensive research efforts, to date only one drug, the thrombolytic agent tPA, has been approved by the FDA for stroke treatment. A number of alternative neuroprotective approaches have been identified in animal ischemia models, but failed in clinical trials. Therefore there is continuous need for development and improvement of novel stroke therapies. In this study we propose to test the novel HYPOTHESIS that oxidative stress potently augments and propagates ischemic brain damage by enhancing glial glutamate release via activation of redox-sensitive glutamate transport pathways. Studies from this and other laboratories has identified three redox-sensitive glutamate release pathways: volume-regulated anion channels (VRAC), the cystine/glutamate antiporter (xCT), and the connexin hemichannels (Cxs). In the proposed work we will use pure and mixed primary cultures of rat astrocytes and microglial cells to find the optimal approaches for reducing pathological glutamate release from glia. This will be followed by testing novel pharmacological treatments in vivo, in a rat model of transient focal ischemia. The following SPECIFIC AIMS are proposed: (AIM 1) to elucidate relative contribution of VRAC, xCT, and Cxs to glutamate release in response to oxidative stress in primary glial cultures, using pharmacological tools and an siRNA approach; (AIM 2) to identify the relationship between oxidative stress and pathological glutamate release in vivo in a rat model of transient focal ischemia, using a microdialysis approach and the intra-dialysate drug delivery; (AIM 3) to test the neuroprotective potential of the pharmacological treatments validated in AIMS 1 and 2, by measuring brain infarction volumes in the control ischemia group and after treatment with neuroprotectants. The major objective of this study is to establish a new fundamental relationship between tissue production of reactive oxygen species and pathological glutamate release from glial cells, and to identify novel pharmacological targets in stroke and other neurological disorders (such as multiple sclerosis, Alzheimer's disease, and traumatic brain injury), which involve oxidative stress.
描述(申请人提供):在美国和其他工业化国家,中风是第三大致死原因,也是导致长期残疾的首要原因。每年有75万美国人罹患中风,超过15万人死于新发和反复发作的中风。尽管进行了广泛的研究,但到目前为止,只有一种药物--溶栓剂tPA--被FDA批准用于中风治疗。在动物缺血模型中已经确定了许多替代的神经保护方法,但在临床试验中失败了。因此,不断需要开发和改进新的卒中疗法。在这项研究中,我们建议检验这一新的假设,即氧化应激通过激活氧化还原敏感的谷氨酸运输途径来促进神经胶质谷氨酸的释放,从而有效地增加和传播缺血性脑损伤。来自该实验室和其他实验室的研究已经确定了三个对氧化还原敏感的谷氨酸释放途径:容量调节阴离子通道(Vrac)、胱氨酸/谷氨酸逆向转运体(XCT)和连接蛋白半通道(CXS)。在这项拟议的工作中,我们将使用大鼠星形胶质细胞和小胶质细胞的纯原代培养和混合原代培养,寻找减少胶质细胞病理性谷氨酸释放的最佳方法。随后,将在短暂性局灶性脑缺血的大鼠模型中,在体内测试新的药物治疗方法。提出了以下具体目标:(目的1)利用药理学工具和siRNA方法,阐明vrac、XCT和CXS对原代培养的胶质细胞氧化应激释放谷氨酸的相对贡献;(目的2)使用微透析法和透析液中的药物释放方法,确定氧化应激与病理性谷氨酸释放之间的关系;(目的3)通过测量对照组缺血组和神经保护剂治疗后的脑梗塞体积,测试目标1和2中验证的药物治疗的神经保护潜力。本研究的主要目的是建立组织产生的活性氧与神经胶质细胞的病理性谷氨酸释放之间的新的基本关系,并确定与氧化应激有关的中风和其他神经疾病(如多发性硬化症、阿尔茨海默病和创伤性脑损伤)的新的药理靶点。
项目成果
期刊论文数量(19)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Volume-regulated anion channel--a frenemy within the brain.
- DOI:10.1007/s00424-015-1765-6
- 发表时间:2016-03
- 期刊:
- 影响因子:0
- 作者:Mongin AA
- 通讯作者:Mongin AA
Calcium-activated potassium channels BK and IK1 are functionally expressed in human gliomas but do not regulate cell proliferation.
- DOI:10.1371/journal.pone.0012304
- 发表时间:2010-08-20
- 期刊:
- 影响因子:3.7
- 作者:Abdullaev IF;Rudkouskaya A;Mongin AA;Kuo YH
- 通讯作者:Kuo YH
Metabolic constraints of swelling-activated glutamate release in astrocytes and their implication for ischemic tissue damage.
星形胶质细胞中肿胀激活的谷氨酸释放的代谢限制及其对缺血性组织损伤的影响。
- DOI:10.1111/jnc.14711
- 发表时间:2019
- 期刊:
- 影响因子:4.7
- 作者:Wilson,CorinneS;Bach,MartinD;Ashkavand,Zahra;Norman,KennethR;Martino,Nina;Adam,AlejandroP;Mongin,AlexanderA
- 通讯作者:Mongin,AlexanderA
The signaling role for chloride in the bidirectional communication between neurons and astrocytes.
- DOI:10.1016/j.neulet.2018.01.012
- 发表时间:2019-01-10
- 期刊:
- 影响因子:2.5
- 作者:Wilson CS;Mongin AA
- 通讯作者:Mongin AA
Activation of P2Y receptors causes strong and persistent shrinkage of C11-MDCK renal epithelial cells.
P2Y 受体的激活导致 C11-MDCK 肾上皮细胞强烈且持续的收缩。
- DOI:10.1152/ajpcell.00018.2011
- 发表时间:2011
- 期刊:
- 影响因子:0
- 作者:Koltsova,SvetlanaV;Platonova,Alexandra;Maksimov,GeorgyV;Mongin,AlexanderA;Grygorczyk,Ryszard;Orlov,SergeiN
- 通讯作者:Orlov,SergeiN
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander A Mongin其他文献
Alexander A Mongin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander A Mongin', 18)}}的其他基金
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
10547819 - 财政年份:2019
- 资助金额:
$ 33.39万 - 项目类别:
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
9765947 - 财政年份:2019
- 资助金额:
$ 33.39万 - 项目类别:
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
8471939 - 财政年份:2009
- 资助金额:
$ 33.39万 - 项目类别:
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
7736456 - 财政年份:2009
- 资助金额:
$ 33.39万 - 项目类别:
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
8287053 - 财政年份:2009
- 资助金额:
$ 33.39万 - 项目类别:
Oxidative Stress and Pathological Glutamate Release in Stroke
中风中的氧化应激和病理性谷氨酸释放
- 批准号:
8113347 - 财政年份:2009
- 资助金额:
$ 33.39万 - 项目类别:
Defects of Neurotransmission in Ischemia and Reperfusion
缺血和再灌注中神经传递的缺陷
- 批准号:
7197100 - 财政年份:2007
- 资助金额:
$ 33.39万 - 项目类别:
Defects of Neurotransmission in Ischemia and Reperfusion
缺血和再灌注中神经传递的缺陷
- 批准号:
7350929 - 财政年份:2007
- 资助金额:
$ 33.39万 - 项目类别:
INTRACELLULAR SIGNALING IN GLIAL CELL VOLUME REGULATION
胶质细胞体积调节中的细胞内信号传导
- 批准号:
2858697 - 财政年份:1997
- 资助金额:
$ 33.39万 - 项目类别:
INTRACELLULAR SIGNALING IN GLIAL CELL VOLUME REGULATION
胶质细胞体积调节中的细胞内信号传导
- 批准号:
2384766 - 财政年份:1997
- 资助金额:
$ 33.39万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 33.39万 - 项目类别:
Research Grant














{{item.name}}会员




